By using Fab'-enzyme labelled immuno absorbent assay (ELISA) with sensitivity of picogram (10-12 g or pg) level, the M-type pyruvate kinase (M-PyK) in plasma was determined in 47 cases of normal healthy adult and ...By using Fab'-enzyme labelled immuno absorbent assay (ELISA) with sensitivity of picogram (10-12 g or pg) level, the M-type pyruvate kinase (M-PyK) in plasma was determined in 47 cases of normal healthy adult and 26 cases of hepatocellular carcinoma (HCC) patient. It was found that the upper limits of normal male and female were 1.1 and 1.4 ng/ml (expressed as M2-PyK) respectively. The plasma M-PyK in HCC patients was significant increased to above 5 times of average normal level, the positive rate was about 95%. In 6 cases of subclinical small hepatocarcinoma and 7 cases of HCC patient with normal serum alpha-fetal protein level, the mean plasma M-PyK value was also increased. Whereas the plasma M-PyK level in acute or chronic hepatitis and other benign diseases were normal. After the HCC being resected, the plasma M-PyK returned to normal, but increased again in the cases of recurrent hepatocarcinoma, suggesting that the increased M-PyK in the plasma of HCC patient was criginated from M2-type PyK in HCC tissue. Therefore, plasma M-PyK may become a new micro-level index of hepatocarcinoma.展开更多
Photothermal therapy(PTT)has received a lot of attention as a promising strategy for eliminating tumors quickly.However,the unavoidable inflammatory response during the treatment might result in a high concentration o...Photothermal therapy(PTT)has received a lot of attention as a promising strategy for eliminating tumors quickly.However,the unavoidable inflammatory response during the treatment might result in a high concentration of M2-like tumor-associated macrophages(TAMs),increasing the risk of tumor recurrence and metastasis.To address this problem,gold-based nanocarriers(PGMP-small interfering RNA(siRNA)nanoparticles(NPs))containing STAT6siRNA,that inhibited M2-like TAM polarization,were designed and investigated for PTT and gene therapy of non-small cell lung cancer(NSCLC).In an NSCLC model,the nanocarriers demonstrated excellent siRNA delivery ability and a high gene transfection rate of up to 90%in macrophages,thus inhibiting the polarization of about 87%of M2-like TAMs and effectively suppressing the invasion and metastasis of NSCLC.Meanwhile,the unique gold nanosphere structure offered improved PTT and contrast-enhanced ultrasound imaging,thus contributing to the efficient elimination and real-time monitoring of the tumor tissues.These nanocarriers with combined gene and photothermal therapeutic capabilities improved the efficacy of single-modality treatment,and showed the potential to inhibit cancer cell recurrence and metastasis to ultimately cure NSCLC.展开更多
文摘By using Fab'-enzyme labelled immuno absorbent assay (ELISA) with sensitivity of picogram (10-12 g or pg) level, the M-type pyruvate kinase (M-PyK) in plasma was determined in 47 cases of normal healthy adult and 26 cases of hepatocellular carcinoma (HCC) patient. It was found that the upper limits of normal male and female were 1.1 and 1.4 ng/ml (expressed as M2-PyK) respectively. The plasma M-PyK in HCC patients was significant increased to above 5 times of average normal level, the positive rate was about 95%. In 6 cases of subclinical small hepatocarcinoma and 7 cases of HCC patient with normal serum alpha-fetal protein level, the mean plasma M-PyK value was also increased. Whereas the plasma M-PyK level in acute or chronic hepatitis and other benign diseases were normal. After the HCC being resected, the plasma M-PyK returned to normal, but increased again in the cases of recurrent hepatocarcinoma, suggesting that the increased M-PyK in the plasma of HCC patient was criginated from M2-type PyK in HCC tissue. Therefore, plasma M-PyK may become a new micro-level index of hepatocarcinoma.
基金This work was supported by the Natural Science Foundation of China(Nos.81873898,81960316,81871411,32011530115,and 32025021)the Science&Technology Bureau of Ningbo City(Nos.2020Z094 and 2021Z072)+1 种基金the Excellent Member of Youth Innovation Promotion Association Foundation of CAS(No.Y2021079)the Ningbo 3315 Innovative Teams Program,China(No.2019A-14-C).
文摘Photothermal therapy(PTT)has received a lot of attention as a promising strategy for eliminating tumors quickly.However,the unavoidable inflammatory response during the treatment might result in a high concentration of M2-like tumor-associated macrophages(TAMs),increasing the risk of tumor recurrence and metastasis.To address this problem,gold-based nanocarriers(PGMP-small interfering RNA(siRNA)nanoparticles(NPs))containing STAT6siRNA,that inhibited M2-like TAM polarization,were designed and investigated for PTT and gene therapy of non-small cell lung cancer(NSCLC).In an NSCLC model,the nanocarriers demonstrated excellent siRNA delivery ability and a high gene transfection rate of up to 90%in macrophages,thus inhibiting the polarization of about 87%of M2-like TAMs and effectively suppressing the invasion and metastasis of NSCLC.Meanwhile,the unique gold nanosphere structure offered improved PTT and contrast-enhanced ultrasound imaging,thus contributing to the efficient elimination and real-time monitoring of the tumor tissues.These nanocarriers with combined gene and photothermal therapeutic capabilities improved the efficacy of single-modality treatment,and showed the potential to inhibit cancer cell recurrence and metastasis to ultimately cure NSCLC.
